Spyre Therapeutics, Inc. (SYRE) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 6 Buy.
The consensus price target is $51.00 (low: $49.00, high: $53.00), representing a downside of 26.1% from the current price $68.99.
Analysts estimate Earnings Per Share (EPS) of $-4.25 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.56 vs est $-4.25 (beat +86.8%). 2025: actual $-1.98 vs est $-2.07 (beat +4.2%). Analyst accuracy: 0%.
SYRE Stock — 12-Month Price Forecast
$51.00
▼ -26.08% Downside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Spyre Therapeutics, Inc., the average price target is $51.00, with a high forecast of $53.00, and a low forecast of $49.00.
The average price target represents a -26.08% change from the last price of $68.99.
Highest Price Target
$53.00
Average Price Target
$51.00
Lowest Price Target
$49.00
SYRE Analyst Ratings
Buy
Based on 6 analysts giving stock ratings to Spyre Therapeutics, Inc. in the past 3 months
EPS Estimates — SYRE
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.56
vs Est –$4.25
▲ 658.5% off
2025
Actual –$1.98
vs Est –$2.07
▲ 4.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — SYRE
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
